

Alanine Expansions Associated With Congenital Central Hypoventilation Syndrome Impair PHOX2B Homeodomain-Mediated Dimerisation And Nuclear Import

Simona Di Lascio^{1#}, Debora Belperio^{1#}, Roberta Benfante^{1,2} and Diego Fornasari^{1,2*}

¹Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano,
Milan, Italy

²CNR Neuroscience Institute, Milan, Italy

#These authors contributed equally to this work

Running title: PHOX2B mutations affect dimerisation and nuclear import

*To whom correspondence should be addressed: Dr. Diego Fornasari, Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129 Milano, Italy, Tel. +39 02 503 16960; Fax +39 02 503 17132, E-mail: diego.fornasari@unimi.it

Keywords: trinucleotide repeat disease; transcription factor; homeobox; dimerization; protein import; protein misfolding; mammalian two hybrid; Congenital Central Hypoventilation Syndrome; PHOX2B; PHOX2A

ABSTRACT

Heterozygous mutations of the human *PHOX2B* gene, a key regulator of autonomic nervous system development, lead to Congenital Central Hypoventilation Syndrome (CCHS), a neurodevelopmental disorder characterised by a failure in the autonomic control of breathing. Polyalanine expansions in the 20-residues region of the C-terminus of PHOX2B are the major mutations responsible for CCHS. Elongation of the alanine stretch in PHOX2B leads to a protein with altered DNA-binding, transcriptional activity and nuclear localisation, and the possible formation of cytoplasmic aggregates; furthermore, the findings of various studies support the idea that CCHS is not due to a pure loss of function mechanism, but also involves a dominant-negative effect and/or toxic gain of function for PHOX2B mutations. As PHOX2B forms homodimers and heterodimers with its paralogue PHOX2A *in vitro*, we tested the hypothesis that the dominant-negative effects of the mutated proteins are due to non-functional interactions with the wild-type protein or PHOX2A using co-immunoprecipitation assay and the mammalian two-hybrid system. Our

findings show that PHOX2B forms homodimers, heterodimerise weakly with mutated proteins, exclude the direct involvement of the polyalanine tract in dimer formation, and indicate that mutated proteins retain partial ability to form heterodimers with PHOX2A. Moreover, in this study we investigated the effects of the longest polyalanine expansions on the homeodomain-mediated nuclear import and our data clearly show that the expanded C-terminus interferes with this process. These results provide novel insights into the effects of the alanine tract expansion on PHOX2B folding and activity.

INTRODUCTION

Heterozygous mutations in the *PHOX2B* gene lead to Congenital Central Hypoventilation Syndrome (CCHS, OMIM ID: 209880), which is characterised by a failure in the autonomic control of breathing and an abnormal ventilatory response to hypoxia and hypercapnia (1). CCHS patients have a greater predisposition to Hirschsprung's disease (HSCR) and neuroblastoma (NB) (2,3), as well as the

symptoms of general autonomic nervous system (ANS) dysfunction (4).

The transcription factor PHOX2B (paired-like homeobox 2b, also known as PMX2B and NBPhox) is a master regulator of ANS development (5), and its human orthologue is a 314 amino acid protein that harbours a homeodomain and two polyalanine stretches of respectively 9 and 20 residues within the C-terminal domain (6,7).

The large majority of CCHS patients carry mutations that cause an expansion of the longer polyalanine repeat (polyalanine repeat expansion mutations, PARMs) (2,8) ranging from +5 to +13 alanine residues, and it has been reported that there is a correlation between the length of the polyalanine tract and the severity of the respiratory phenotype and autonomic dysfunction (8,9). Non-polyalanine repeat mutations (NPARMs: i.e. missense, nonsense and frameshift mutations) are less frequent, but correlate with more severe respiratory symptoms, HSCR and NB.

From a functional point of view, it is well established that the homeodomain of PHOX2B is a highly conserved 60-residues region that contains the DNA-binding motif; furthermore, in line with what has been observed in other homeodomain proteins, the PHOX2B homeodomain may also contain nuclear localisation signals, be responsible for the formation of homo- and heterodimers (with other homeoproteins, including its paralogue PHOX2A), and establish protein-protein interactions (10). On the contrary, the exact molecular functions of the polyalanine tracts remain largely unknown.

Polyalanine and, more generally, homopolymeric tracts (single amino acid repeats) are common features of eukaryotic proteins and especially abundant in transcription factors (11,12). Increasing experimental data show that they can modulate transcription factor activity by acting as flexible spacer elements located between functional protein domains, and therefore play a role in protein conformation, protein-protein interactions, and/or DNA binding (13-15). The coding triplet repeat instability that leads to the expansion of these stretches causes a number of human diseases (16,17), all of which are characterised by protein misfolding that leads to intracellular

aggregation, which may be an intrinsic tendency because, beyond a certain threshold, the polyalanine tracts spontaneously form β -sheets *in vitro* (18).

Increasingly long polyalanine tracts also lead to an increased tendency for protein aggregation and possible toxic effects in the case of PHOX2B (19,20). Nuclear import defects and cytoplasmic aggregation are detectable only in the case of proteins with longer expansions, whereas, other defects, such as decreased DNA-binding and transcriptional activity, characterize also shorter expansions (19-21). In addition to loss-of-function defects, it has been reported that the mutant protein with the longest expansion (+13 alanine) has a dominant-negative effect on the DNA-binding and subcellular localisation of the wild-type protein (19,21,22). Furthermore, the negative effects of PHOX2B mutant proteins on the transcriptional activity of the wild-type protein are promoter-specific (20,21), but it is not clear if the observed functional effects are the result of direct aberrant interactions between wild-type and mutant proteins and/or with other proteins. It should be noted that the absence of co-aggregation of the wild-type protein with mutants with the shorter expansions, revealed by immunofluorescence, does not exclude the possibility of interactions between the non-aggregated proteins at the molecular level.

As wild-type PHOX2B forms homodimers *in vitro*, as well as an important fraction of the mutants with shorter expansions (7,20), and that our previous *in vitro* results suggest the possible formation of non-functional heterodimers (21), we decided to test this hypothesis using co-immunoprecipitation assay and mammalian two-hybrid system.

Furthermore, using the same approaches, we assess the ability of mutated proteins to form heterodimers with PHOX2A.

Moreover, given the central role of the homeodomain in DNA binding, nuclear import and dimerisation, we also exploit the effects of the alanine tract expansion on PHOX2B nuclear import process.

MATERIALS AND METHODS

Plasmid construction

All of the oligonucleotides used to generate the constructs are listed in Table 1. The PCR

amplifications were performed using the GC-rich PCR system (Roche), and all of the DNA fragments obtained by PCR were sequenced on both strands. All of the enzymes used for cloning were purchased from New England Biolabs.

Expression plasmids.

The MYC-tagged PHOX2B wild-type, +7 alanine and +13 alanine mutant plasmids have been described previously (19,21,22).

The generation of the expression plasmid HA-tagged PHOX2B wild-type (HA-PHOX2B WT) has been described elsewhere (21). The PHOX2B deletion constructs (Nter, Nter + HD, HD, HD + Cter, Cter) were obtained by amplifying specific regions of PHOX2B cDNA using HA-PHOX2B WT as the PCR template. The primers used contain the EcoRI restriction site and, after enzymatic digestion with EcoRI, the PCR products were inserted into the HA-PHOX2B WT vector after same enzyme had been used to remove PHOX2B cDNA. The HD + Cter +13Ala and the Cter +13Ala constructs were obtained by digesting the corresponding wild-type plasmids containing the normal alanine tract with the PpuMI restriction enzyme. The resulting 270 bp region, which encompasses the alanine tract, was replaced by the 309 bp region obtained using the same enzyme to digest the Myc-tagged PHOX2B +13Ala plasmid (19,22).

The HA-PHOX2B Δ NLS1, HA-PHOX2B Δ NLS2 and HA-PHOX2B Δ 106-147 constructs were made using overlap extension PCR (23) with the HA-PHOX2B WT plasmid as the template. Two chimeric primers were used for each construct, each of which consisted of an annealing fragment derived from one flanking region of the deletion, and an anchor fragment derived from the flanking region on the other side of the deletion. The external primers were used to insert the deletions in all of the PCR experiments. The first PCR was performed using 40 ng of super-coiled plasmid containing PHOX2B cDNA in order to amplify two partially overlapping DNA fragments carrying the deletion. The two purified fragments were then annealed and used as the template (50 ng/each) for a second PCR using the external primers to obtain a single product. The PCR products were cloned after double enzymatic digestion with HindIII/PpuMI in the HA-PHOX2B WT plasmid, and the 270 bp region,

which was removed by means of PpuMI enzymatic digestion, was subsequently inserted into the resulting plasmid after digestion with the same enzyme. The HA-PHOX2B Δ NLS1-2 plasmid was obtained by means of the same strategy using the HA-PHOX2B Δ NLS2 plasmid as the template, and PHOX2B Δ NLS1 FW and REV primers.

The HA-PHOX2B +13Ala, HA-PHOX2B Δ NLS1 +13Ala, HA-PHOX2B Δ NLS2 +13Ala and HA-PHOX2B Δ NLS1-2 +13Ala constructs were generated by means of enzymatic digestion with PpuMI and the replacement of the region encompassing the two PpuMI restriction sites containing the normal alanine stretch with the expanded stretch.

The MYC- and HA-tagged PHOX2A expression vectors were obtained by cloning human PHOX2A cDNA (24) into the EcoRI site of pCMV-MYC or pCMV-HA (Clontech Laboratories Inc., Mountain View, CA, USA).

The Mammalian two-hybrid system plasmids.

The CheckMate Mammalian two-Hybrid system kit (Promega) was used to provide the pBIND vector containing the yeast GAL4 DNA-binding domain (BD) and *Renilla reniformis* luciferase under the control of the SV40 promoter, the pACT vector containing the herpes simplex virus VP16 activation domain (AD), and the pG5LUC plasmid containing five GAL4 binding sites upstream of a minimal TATA box and the firefly luciferase gene.

The plasmids encoding GAL4 BD-PHOX2B, VP16 AD-PHOX2B, VP16 AD-Nter, -Nter + HD, -HD, -HD + Cter, and -Cter were generated by means of PCR using primers containing the KpnI restriction site. The HA-PHOX2B WT plasmid was used as the PCR template, and the PCR products were cloned in the pBIND and pACT vectors after KpnI enzymatic digestion.

The GAL4 BD-PHOX2B +7Ala/ +13Ala/ Δ Ala and the VP16 AD-PHOX2B +7Ala/ +13Ala/ Δ Ala mutant plasmids were obtained by means of PpuMI enzymatic digestion of the corresponding wild-type plasmids. The 270 bp fragment between the two PpuMI restriction sites was replaced by the corresponding regions containing the expanded or deleted alanine stretches, which were isolated from the previously described expression plasmids HA-PHOX2B 0Ala, PHOX2B +7Ala (21) and

PHOX2B +13Ala (19,22) by means of enzymatic digestion using the same enzyme.

The plasmids encoding GAL4 BD-PHOX2A and VP16 AD- PHOX2A were generated by means of PCR using primers containing the NotI restriction site. The PHOX2A in pCDNA3 plasmid was used as the PCR template (24), and the PCR products were cloned in the pBIND and pACT vectors after NotI enzymatic digestion.

Reporter plasmids.

The *DBH* promoter reporter plasmid construct was obtained by cloning a 993 bp *DBH* regulatory region into pGL4 basic vector (Promega), as previously described (21).

Cell cultures, transient transfections and luciferase assays

The HeLa cells were grown in Dulbecco's modified Eagle's medium (Lonza), and the SK-N-BE(2)C cells were maintained in RPMI 1640 without L-glutamine (Lonza). Each medium was supplemented with 10% fetal calf serum (PAA), 100 units/mL penicillin (Lonza), 100 µg/mL streptomycin (Lonza) and 2mM L-glutamine (Lonza).

The cells were transiently transfected or co-transfected by means of lipofection (FUGENE HD, Promega) as previously described (21,25,26) using 1.5×10^5 SK-N-BE(2)C or 5×10^4 HeLa cells.

In mammalian two-hybrid experiments 80 fmol of each expression vector were combined with 160 fmol of pG5LUC plasmid. The luciferase assay was carried out using the Dual Luciferase Reporter Assay System (Promega) as previously described (26,27). All of the transfections were performed in triplicate, and each construct was tested in at least three independent experiments using different batches of plasmid preparation. The numbers of independent transfection experiments are indicated in the figure legends.

Immunofluorescence

Immunofluorescence was performed as previously described (25). HeLa cells plated on 1.7×1.7 cm² glass coverslips were grown to 50% confluence and transfected with the expression plasmid of interest (160 fmol of DNA). The HA-tagged PHOX2B proteins were detected by means of primary rabbit anti-HA antibody (1:50, Sigma, #H6908) and the secondary Alexa Fluor

488 anti-rabbit antibody (1:400, Invitrogen, #A11034).

The GAL4 BD and VP16 AD fusion proteins (except for VP16 AD-Nter, VP16 AD-Nter + HD, and VP16 AD-HD) were analysed using primary chicken anti-PHOX2B antibody (1:100, (25)) and the secondary DyLight 549-conjugated donkey anti-chicken antibody (1:200, Jackson ImmunoResearch, Inc., West Grove, Pennsylvania, USA, #703-505-155). The VP16 AD-Nter, VP16 AD-Nter + HD, and VP16 AD-HD proteins were analysed using mouse VP16 antibody (Santa Cruz Biotechnology, #sc-7546) and the secondary DyLight 549-conjugated goat anti-mouse antibody (1:400, Jackson ImmunoResearch, #115-505-146). The nuclei were stained with DAPI, and the images were acquired using an LSM 510 Meta confocal microscope (Carl Zeiss, Inc.) with 63X Nikon Apochromat lenses (1.5 NA).

All the immunofluorescence analyses were replicated three times representing independent transfections and representative images are shown in figures 1, 2, 3, 6, 7, 8 and 9.

Electrophoretic mobility shift assays (EMSAs)

The EMSAs were performed as previously described (25,28). The *in vitro* expression of PHOX2A, wild-type PHOX2B and the deletion and mutant variants was obtained using a commercially available rabbit reticulocyte lysate system (TNT Quick-coupled Transcription/Translation System, Promega) as previously described (25). The oligonucleotides bearing the ATTA 2 and ATTA 3-4 sites of the *PHOX2B* promoter have been previously described (25). The homeodomain binding site (hbs) oligonucleotide corresponding to the PHOX2B binding site in the *PHOX2A* promoter, and the oligonucleotides PRS1 and PBD2 have been previously described (26,29,30). All of the oligonucleotides were purchased from Sigma-Aldrich. The antibodies used in EMSA experiments are: the rabbit anti-HA antibody (Sigma, #H6908), the chicken anti-PHOX2A and PHOX2B antibody, previously validated and characterised (24,25). The EMSA experiments were replicated at least two times, using different batches of rabbit reticulocyte lysate.

Co-immunoprecipitation assays and Western Blot analyses

HeLa cells (8×10^5) were plated in 100 mm petri dishes and transiently transfected by means of lipofection (FUGENE HD, Promega) with 700 fmol of each expression vector and harvested after 24 h, when the total extracts were prepared for immunoprecipitation. Proteins were extracted in lysis buffer [25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP40, 0.5% Sodium deoxycholate, 1 mM $MgCl_2$, 0.2 mM phenylmethylsulfonyl fluoride, Sigma protease inhibitors mixture, and 250U/mL of Pierce Universal Nuclease For Cell Lysis (Thermo Fisher Scientific)]. Lysates were clarified by 30 min centrifugation at $16,000 \times g$ and $4^\circ C$ to remove cell debris and afterward precleared using 20 μL of protein G/agarose bead slurry (Invitrogen) for 1 hour under constant rotation. The precleared extracts were incubated overnight at $4^\circ C$ with 5 μg of each primary antibody [monoclonal mouse anti-MYC antibody (Sigma Aldrich, #M5546), polyclonal rabbit anti-HA antibody (Sigma Aldrich, #H6908), and preimmune mouse or rabbit IgG (Santa Cruz Biotechnology, #sc-2025 and #sc-2027)], and the immunocomplexes were captured by protein G/agarose bead slurry for 4 h at $4^\circ C$ with rotation.

The beads were collected by centrifugation and gently washed and resuspended in sample loading buffer. The immunocomplexes were dissociated from the beads by boiling the samples, then separated by SDS-PAGE, and transferred on nitrocellulose membrane. Western blotting was performed as described previously (24) using the primary anti-MYC (1:1000; Sigma Aldrich, #M5546), and anti-HA (1:500; Sigma Aldrich, #H6908) antibodies. All the co-immunoprecipitation experiments were replicated three times representing independent transfections and representative immunoblotting images are shown in figures 1-4.

RESULTS

PHOX2B forms homodimers

GST pull-down and gel-filtration chromatography experiments have previously shown that wild-type PHOX2B protein forms homodimers *in vitro* (7,20,31). In order to verify these observations in a more physiological

context that takes into account the possible influences of the cell environmental factors such as interactors and post-translational modifications, we tested the ability of PHOX2B to dimerise by co-immunoprecipitation.

To this end, we transiently transfected HeLa cells, that do not endogenously express PHOX2B, with MYC and HA tagged PHOX2B encoding plasmids and when the proteins were immunoprecipitated with the anti-MYC antibody, the precipitated complex also contained HA-PHOX2B variant (Fig. 1A, lane 2), indicating PHOX2B homodimers formation in mammalian cells. As a control, protein-G agarose beads coated with a pre-immune antibody did not show HA signal after immunoprecipitation (Fig. 1A, lane 3). This positive interaction was confirmed by means of the anti-HA antibody immunoprecipitation (Fig. 2A, lane 2).

Next, we extended our analysis by examining PHOX2B self-interactions using a mammalian two-hybrid system. Thus, we generated PHOX2B fusion proteins respectively with the yeast GAL4 DNA binding domain (GAL4 BD) and herpes simplex virus VP16 activation domain (VP16 AD).

We first tested their expression and subcellular localisation by transfecting GAL4 BD-PHOX2B and VP16 AD-PHOX2B encoding plasmids into HeLa cells, and analysed the transfected cells by means of confocal microscopy upon immunohistochemistry with an antibody directed against PHOX2B C-terminus; as shown in Fig. 1B, both the GAL4 BD-PHOX2B (panels a, c and e) and VP16 AD-PHOX2B (panel b, d and f) proteins localised diffusely in the nucleus.

The two fusion constructs were then co-transfected, alone or in combination, together with a reporter construct containing five GAL4 binding sites upstream of a minimal TATA box controlling the firefly luciferase reporter gene (pG5LUC) into neuroblastoma SK-N-BE(2)C (Fig. 1C) and HeLa cells (Fig. 1D).

When VP16 AD-PHOX2B was co-transfected with the GAL4 DNA binding domain (GAL4 BD) or the VP16 activation domain (VP16 AD) in SK-N-BE(2)C and HeLa cells, no significant increase in luciferase activity was measured in comparison with the empty vectors (GAL4 BD and VP16 AD) (Fig. 1C and D, grey bars vs white bars), excluding non-specific positive

interactions between PHOX2B and VP16 AD or GAL4 BD.

Also GAL4 BD-PHOX2B did not show non-specific interactions with the VP16 activation domain (VP16 AD), as there was little if any increase (in SK-N-BE(2)C cells) or a significant decrease (HeLa cells) in luciferase activity in comparison with the empty vectors (GAL4 BD and VP16 AD) (Fig. 1C and D, hatched vs white bars). This also indicated that PHOX2B does not autonomously activate transcription by the reporter construct. A decrease in luciferase activity has previously been observed in the case of other paired-type homeoproteins, thus suggesting that direct DNA binding by the homeodomain is required for transactivation activity (32-34).

On the contrary, when both fusion constructs (GAL4 BD-PHOX2B and VP16 AD-PHOX2B) were co-transfected in SK-N-BE(2)C (Fig. 1C, black bar) and HeLa cells (Fig. 1D, black bar), there was respectively a 3-fold and an 8-fold increase in luciferase activity, and the lower luciferase activity measured in SK-N-BE(2)C cells was probably due to the lower transfection efficiency, in comparison to HeLa cells. Our results thus indicate that PHOX2B homodimers can be efficiently detected by both using co-immunoprecipitation assay and mammalian two-hybrid system.

PHOX2B polyalanine expanded proteins interact weakly with wild-type protein

Mutant proteins can interfere with the activity of the wild-type protein by forming functionally impaired heterodimers, and thus have a dominant-negative effect. Several data have shown that PHOX2B polyalanine expanded proteins can easily form aggregates, and this has been reasonably interpreted as a consequence of an increased tendency of PHOX2B to self-interact, as has previously observed in the case of long polyalanine stretches and homopolymeric tracts in general (35). Previous gel-filtration experiments have also shown that an important fraction of the mutants with shorter expansions retains the ability to form dimers, whereas there is virtually no formation of species corresponding to the wild-type dimers in the presence of proteins with increasingly long polyalanine tracts (20), and both *in vitro* and *in vivo* experiments suggest the existence of

interactions between wild-type and mutant proteins (20-22).

In order to test the ability of mutant proteins to heterodimerise, we transiently transfected HeLa cells with HA-tagged PHOX2B WT plasmid in combination with MYC-tagged PHOX2B variants carrying the most frequently identified polyalanine expansion in CCHS patients (+7 alanine) or the longest expansion (+13 alanine), and examined their binding potential by co-immunoprecipitation assays.

Our results revealed that mutant proteins immunoprecipitated with PHOX2B wild-type protein, and that there was a progressive weaker interaction of the mutant proteins as a function of the length of the expansion (Fig. 2A, lanes 5 and 8 vs lane 2). Moreover, we observed a reduced amount of mutant proteins in total cell lysates in comparison to wild-type protein (Fig. 2A, lanes 4 and 7 vs lane 1), due to their decreased solubility after detergent extraction, as confirmed by the higher proportion of mutant proteins in the insoluble fraction (data not shown and previously reported (22)). To exclude that the lower signals obtained with the mutants in co-immunoprecipitation experiments were due to the decreased protein solubility, and to confirm our data, we extended our analysis by using the mammalian two-hybrid system. Co-transfection experiments of VP16 AD-PHOX2B +7 Ala or VP16 AD-PHOX2B +13 Ala with GAL4 BD-PHOX2B WT showed no functional interactions between the mutants and wild-type protein in SK-N-BE(2)C cells (Fig. 2C, cross-hatched bars vs hatched bar), and only slight but not statistically significant interactions in HeLa cells, with respect to PHOX2B WT and VP16 AD (Fig. 2D, cross-hatched bars vs hatched bar). Immunofluorescence analysis of HeLa cells transiently transfected with VP16 AD-PHOX2B +7Ala and VP16 AD-PHOX2B +13Ala showed that both mutants localised completely in the nucleus (Fig. 2B, panels a-f), thus suggesting that the insertion of the nuclear localisation signal encoded by the pACT vector is sufficient to force the mutant proteins into the nucleus, particularly the +13 alanine mutants, which usually have a partial cytoplasmic localisation (19-21), and excluding the possibility that the reduced capability of the mutant proteins to interact with the wild-type protein may be due to their improper localisation.

In order to evaluate the ability of the mutants to form homodimers, we fused GAL4 BD to PHOX2B carrying +7 or +13 alanine expansions. Unlike the VP16 fusion proteins, the GAL4 BD fusion proteins were not completely detected in the nucleus, thus confirming their tendency to mislocalise in the cytoplasm and indicating that the nuclear localisation signal encoded by pBIND vector is weaker and unable to counteract their nuclear import defects (Fig. 3A, panels a-f).

In SK-N-BE(2)C cells co-transfection experiments along with pG5LUC plasmid, we found a significant increase in luciferase activity, but the strength of the interactions in mutants forming homodimers was weaker than those observed in wild-type homodimers, probably due to the partial mislocalisation of the GAL4 BD-fusion proteins in the cytoplasm: respectively 1.7- and 2-fold increases in the case of the +7 alanine and +13 alanine mutants homodimers (Fig. 3B and 3C, compare black bars with that one in Fig. 1C). Further, it should be noted that our data concerning interactions among mutants may not allow us to distinguish the formation of dimers and oligomers, but the measured luciferase activities apparently correlate with the increasing propensity of the expanded protein to aggregate as a function of the length of the polyalanine tract. Interactions among mutants were confirmed by co-immunoprecipitation (Fig. 3D, lanes 5 and 11), and the signal obtained with the +13 alanine mutant, compared to its respective input signal, was stronger than that showed by the +7 alanine mutant, thus suggesting, again, a correlation between the increasing formation of oligomers with the length of the polyalanine tract (Fig. 3D, lane 5 vs 4 and lane 11 vs 10).

As protein-protein interactions can be direction-dependent, we also assessed the dimerisation of the mutants and wild-type protein in the opposite orientation but, once again, we observed no functional interactions with the wild-type protein (Fig. 3B and 3C, cross-hatched bars). However, but in accordance to our previous co-immunoprecipitation experiments and those performed in HeLa cells using mammalian two-hybrid system, a small proportion of the wild-type protein was immunoprecipitated with both mutants (Fig. 3D, lanes 2 and 8). These data indicate that the mutant proteins partially form

homodimers and interact very weakly with the wild-type protein, and that this was unlikely to be due to the incorrect localisation of the mutants. However, the partial discrepancy between biochemical and luciferase data did not exclude the possibility that heterodimers are unable to reconstitute a functional transcription factor and thus stimulate transcription from the reporter gene.

PHOX2B polyalanine expanded proteins retain a partial ability to interact with PHOX2A

GST pull-down and EMSA experiments have previously shown that PHOX2B protein and its paralogue PHOX2A forms heterodimers *in vitro* (7,20,31). Over-expression of PHOX2A with PHOX2B +13 alanine mutant did not show co-aggregation or trapping of PHOX2A in the cytoplasm (20). We decided to test the ability of mutant proteins to heterodimerise with PHOX2A by both co-immunoprecipitation and mammalian two-hybrid system.

When the MYC-tagged version of PHOX2A together with HA-tagged PHOX2A or PHOX2B WT were over-expressed in HeLa cells, immunoprecipitation with the anti-MYC antibody showed interaction with both HA-PHOX2A and HA-PHOX2B (Fig. 4A, lanes 2 and 5), thus confirming the formation of PHOX2A homodimers and PHOX2A:PHOX2B heterodimers in mammalian cells. When we tested the ability of PHOX2B mutant proteins to interact with PHOX2A, similarly to our observations on PHOX2B:mutants heterodimers formation, the polyalanine expanded tract reduced the solubility of PHOX2B mutants in comparison to wild-type protein and even more to PHOX2A (Fig. 4A, lanes 1 and 4 and Fig. 4B, lanes 1, 4, and 7) and also their binding to PHOX2A (Fig. 4B, lanes 5 and 8 vs lane 2). In order to exclude the involvement of protein extraction procedure on the reduced interaction between PHOX2A and mutant PHOX2B proteins, we tested homo- and heterodimers formation, by mammalian two-hybrid system. To this end, we fused GAL4 BD and VP16 AD to PHOX2A and first measured the ability of PHOX2A to form homodimers and heterodimers with PHOX2B. As shown in Fig. 4C, the luciferase activity measured when the GAL4BD-PHOX2A protein was co-transfected with the

VP16-counterpart was more than two-fold greater than that obtained using PHOX2B fusion constructs (Fig. 4C, compare white with black bar), thus suggesting that PHOX2A forms homodimers more efficiently than PHOX2B. When we assessed the heterodimerisation of PHOX2A with PHOX2B, we observed that their interaction is stronger than that measured in PHOX2B homodimers (Fig. 4C, cross-hatched and grey bars vs black bar) and direction-dependent (Fig. 4C, cross-hatched vs grey bar). Co-transfection experiments of GAL4 BD-PHOX2A along with VP16- PHOX2B mutant fusion proteins (VP16 AD-PHOX2B +7Ala and VP16 AD-PHOX2B +13Ala) showed that the polyalanine expansions severely affect the ability of PHOX2B to form heterodimers with PHOX2A (Fig. 4C, hatched bars vs grey bar). Nevertheless the strength of the interactions measured between PHOX2A and the PHOX2B mutants was comparable with, or slightly weaker than that of PHOX2A homodimers (Fig. 4C, hatched bars vs white bar), and even higher than that of PHOX2B homodimers (Fig. 4C, hatched bars vs black bar). The above experiments indicate that PHOX2B mutants retain a partial ability to heterodimerise with PHOX2A and, therefore, suggest the possible formation of heterodimers (PHOX2A:PHOX2B mutants) with an efficiency comparable to that of PHOX2A homodimers. To investigate whether the relative strong binding of mutants to PHOX2A might compete with normal PHOX2A homodimerisation, we performed competition experiments by co-transfecting equimolar amounts of PHOX2B WT or mutants encoding plasmids together with GAL4BD- and VP16 AD- tagged PHOX2A. While PHOX2B wild-type protein increased luciferase activity more than two fold (Fig. 4D, black bar vs white bar), both mutants showed a slight but not significant increase of luciferase activity (Fig. 4D, hatched bars vs white bar), thus suggesting that PHOX2A homodimers formation is not affected by the presence of PHOX2B mutants. A possible interpretation of the increased luciferase activity in the presence of the wild-type protein is that PHOX2B might stabilise PHOX2A homodimers formation, and eventually promote transcriptional complex assembly. Remarkably, a similar increase in PHOX2B homodimers activity occurred in the presence of the wild-type

protein (Fig. 4E, black bar vs white bar), whereas a slight reduction was measured in the presence of PHOX2B mutants (Fig. 4E, hatched bars vs white bar).

Our data thus indicate that PHOX2B mutants do not significantly interfere with neither PHOX2B nor PHOX2A homodimerisation.

PHOX2B polyalanine expanded proteins do not interfere with PHOX2A-mediated transactivation of the *DBH* promoter, and, conversely, interact synergistically

Given that PHOX2B mutants retain a partial ability to heterodimerise with PHOX2A, we tested whether PHOX2B mutants might alter PHOX2A-mediated transactivation of the *DBH* (dopamine- β -hydroxylase) promoter, a well-characterized PHOX2A and PHOX2B target gene (7,29,30). As previously reported (19-21), the mutant proteins showed a marked reduction in their ability to induce the correct activation of the *DBH* reporter construct (Fig. 5A, bars 3 and 4 vs bar 2), and co-transfection of the polyalanine expanded proteins with the wild-type protein led to similar luciferase activity to that of the normal PHOX2B alone (Fig. 5A, bars 5 and 6 vs bar 2). When the *DBH* reporter construct was co-transfected together with PHOX2A, we measured a greater induction by PHOX2B WT protein in comparison to PHOX2A (Fig. 5A, bar 2 vs bar 8), differently from that previously reported (7,29,30); this discrepancy could be probably due to the use of a different regulatory region (993 bp vs 232 bp long) and/or reporter plasmid (pGL4 vs pGL3 vector). Moreover, the combination of PHOX2A and PHOX2B increased *DBH*-driven luciferase activity to a slightly (but not significant) lower extent than that obtained with PHOX2B alone (Fig. 5A, bar 7 vs bar 2), confirming that the two factors act independently on the *DBH* promoter (7).

Interestingly, the luciferase activity measured when PHOX2A was co-transfected with the + 7 alanine mutant protein was lower but more comparable with that obtained using the wild-type counterpart (respectively, 23 and 32 folds over the empty vector), suggesting a (novel) synergistic interaction between the two proteins (Fig. 5A, bar 9 vs bar 7). A lower synergistic interaction was observed by combining the +13

alanine mutant with PHOX2A (Fig. 5A, bar 10), although not statistically significant.

As PHOX2B mutants showed diminished DNA binding (20,21), we tested by EMSAs whether the observed transcriptional effects correlated with alterations in their DNA binding properties in the presence of PHOX2A; we used the oligonucleotide corresponding to the site in the *DBH* promoter to which PHOX2A/2B bind as dimers (30). As previously reported with other PHOX2B binding sites (20,21), the expansion of the polyalanine tract progressively reduced DNA binding (Fig. 5B, lanes 9 and 12 vs lane 6), with the DNA-+13 alanine mutant complex severely affected and hardly detectable.

The retarded band obtained with the *in vitro* expressed PHOX2A protein was undetectable in this set of experiments (Fig. 5B, lane 3), probably reflecting the relative low affinity of this consensus site and/or the lower binding ability of the *in vitro* expressed protein compared to the PHOX2A-containing nuclear lysates (24,30,36,37); however, a strong ultra-retarded band could be obtained in the presence of the anti-PHOX2A antibody (Fig. 5B, lane 5). This effect was not due to the interaction of the antibody with other proteins contained in the reticulocyte lysate, as we had previously shown that both PHOX2A and PHOX2B antibodies did not recognise any protein in the lysate (24, 25), but it is in line with previous evidences showing that the antibody may stabilise the interactions between PHOX2A and PHOX2B and their cognate DNA binding sites (21,24,25,36). No specific band was detectable in the presence of reticulocyte lysate programmed with the empty vector pcDNA3 (Fig. 5B, lane 2), thus excluding non-specific interactions of the lysate with this probe.

When PHOX2A was combined with PHOX2B, a more intense retarded band than that with the PHOX2B wild-type protein alone was obtained (Fig. 5B, lane 15 vs lane 6), and the antibody directed against PHOX2A supershifted a more intense band than that observed using the PHOX2A protein alone (Fig. 5B, lane 17 vs lane 5), suggesting that heterodimers formed of both proteins have a higher DNA binding affinity. Interestingly, a band is still visible in the presence of the antibody against PHOX2A, indicating that only a fraction of the PHOX2B protein forms heterodimers with PHOX2A (Fig.

5B, lane 17). Similarly to that obtained with the wild-type protein, the retarded bands observed when the +7 and the +13 alanine mutants were mixed with PHOX2A were more intense than those detected with the expanded proteins alone (Fig. 5B, lane 19 vs 9 and lane 23 vs 12). Notably, more intense supershifted bands were observed using the antibody against the PHOX2B mutants, indicating a partial rescue of the DNA binding of the mutants in the presence of PHOX2A (Fig. 5B, lane 22 vs 11 and lane 26 vs 14).

The dimerisation domain encompasses the homeodomain and the C-ter region of PHOX2B and does not involve the alanine stretch

Although the predictable central role of the homeodomain in PHOX2B dimerisation, as our data from mammalian two-hybrid system experiments indicated that PHOX2B carrying polyalanine expanded stretches are unable to interact with wild-type protein but at least partially conserved an ability to homodimerise, we estimated the involvement of the alanine tract in dimer formation by generating two constructs expressing a polyalanine-deleted PHOX2B protein fused to the GAL4 BD or VP16 AD domain (GAL4BD-PHOX2B Δ Ala and VP16-PHOX2B Δ Ala). As shown in Fig. 6A, the deletion of the polyalanine tract did not affect the intracellular localisation of the proteins, as previously reported by Di Lascio *et al.* (21). The luciferase activity measured when the GAL4BD-PHOX2B WT protein was co-transfected with the VP16-polyalanine deleted protein was comparable with, or even slightly greater than that obtained using the wild-type counterpart, thus suggesting that the deleted alanine tract does not affect the ability of PHOX2B to dimerise (Fig. 6B, compare black with cross-hatched bar). We likewise also detected strong homodimerisation with the GAL4BD-PHOX2B Δ Ala and VP16-PHOX2B Δ Ala fusion proteins, thus confirming the small contribution of the alanine stretch to the dimerisation properties of PHOX2B (Fig. 6C, black bar).

In order to map the protein dimerisation domain, a series of VP16 fusion constructs containing fragments of PHOX2B protein were generated on the basis of its homeodomain boundaries (Fig. 7B). We first used immunofluorescence to

check the expression and localisation of the deleted proteins. The VP16-PHOX2B 1-157 containing the homeodomain and the N-terminal region (Fig. 7A, panels d-f; Nter + HD), VP16-PHOX2B 98-157 corresponding to the homeodomain (Fig. 7A, panels g-i; HD), VP16-PHOX2B 98-314 including the homeodomain and the C-terminal region (Fig. 7A, panels l-n; HD + Cter) and the VP16-PHOX2B 155-314 construct containing the C-terminal region (Fig. 7A, panels o-q; Cter), all predominantly localised in the nucleus. Unexpectedly, the proteins containing the N-terminal region (i.e. Nter and Nter + HD) respectively showed a very strong tendency to aggregate in the cytoplasm (Fig. 7A, panels a-c) and nucleus (Fig. 7A, panels d-f).

We therefore co-transfected the deleted proteins (excluding the construct containing the N-terminal region because it is localised in the cytoplasm) with the GAL4BD-PHOX2B WT protein. A significant increase in luciferase activity was observed only with the fragment corresponding to the C-terminal and homeodomain (2B 98-314), but it was less than that obtained using the full-length protein (Fig. 7B, compare cross-hatched bars with black bar); luciferase activity was comparable with that of the background in the case of the C-terminal fragment alone (2B 155-314), and only two fold above the background in the case of the fragment containing the N-terminal region and homeodomain (2B 1-157).

The findings of previous studies of other homeoproteins suggest that the region at the end of the homeodomain (helix III) might be critical for dimer formation (34,38). Bearing in mind the spot-like distribution of the protein lacking the C-terminal region (Nter + HD) that could interfere with this process, we generated a deletion construct missing the region at the end of the homeodomain (encompassing amino acids 148–155). The obtained protein did not interact with the wild-type protein but, once again, aggregated in the nucleus (data not shown). Furthermore, the luciferase activity of the VP16 AD-HD construct (corresponding to the homeodomain) was comparable with that of the background and that obtained using the C-terminal fragment alone (Fig. 7B, 2B 98-157), thus suggesting that the presence and integrity of both domains are required for PHOX2B

dimerisation. We also found slightly lower luciferase activity in the absence of the N-terminal domain, although not statistically significant compared with that obtained with the full-length protein, thus not excluding the possibility that the N-terminal domain may also play a role in the dimerisation process.

We also evaluated the role of the C-terminal and N-terminal domains in dimer formation and DNA binding using EMSAs and radio-labelled oligonucleotides corresponding to the *PHOX2B* promoter region containing ATTA core motifs known to bind PHOX2B (ATTA 2 and ATTA 3-4 motifs) (21,25), the probe corresponding to the PHOX2B binding site in the *PHOX2A* promoter (26,39), and the PRS1 oligonucleotide corresponding to a region within domain IV of the *DBH* promoter (29).

Incubation of the wild-type protein with each radio-labelled oligonucleotide caused the appearance of specific retarded bands (complexes I and II) that could be competed by a molar excess of cold oligonucleotide, and super-shifted by the anti-HA antibody (Fig. 7C and 7D, lanes 1-3 and 11-13,*). Conversely, DNA binding of the C-terminal deleted protein (Nter + HD) to all the probes was severely affected (Fig. 7C and 7D, lanes 7-9 and 17-19), although a weak complex could be detected in the presence of the HA antibodies (Fig. 7C, lanes 9 and 19, ***) with the exception of the ATTA 3-4 motif, which suggests that the antibody may stabilise interactions between the truncated protein and DNA. The behaviour of the N-terminal deleted protein (HD + Cter) was different: the migration of complexes I and II was faster because of the smaller size of the protein (complexes Ia and IIa), and the deleted protein retained a partial ability to bind DNA (Fig. 7C and 7D, lanes 4-6 and 14-16), with complex Ia being the most affected. The same oligonucleotide shown in Fig. 7D (corresponding to a region of the *DBH* promoter and containing two homeodomain binding sites) has previously been used with PHOX2A protein in EMSA experiments (30), and it is worth noting that two DNA/protein complexes were observed: one formed when PHOX2A binds a single site as a monomer, and another more retarded complex when two PHOX2A molecules simultaneously binds both sites (probably as monomers). We obtained a similar pattern (complex I and II) using the

PHOX2B promoter (ATTA 3-4 motifs) and the DBH promoter probes, both of which contain two ATTA motifs in tandem position with respectively seven and six intervening bases (underlined in Fig. 7C and 7D), thus suggesting that PHOX2B binds to those sites in DBH and PHOX2B promoter mainly as monomer. Moreover, the authors also showed that PHOX2A binds two other probes as a dimer containing a single motif and a second potential incomplete motif with three intervening bases. As comparison of the nucleotide sequences of the probes containing the ATTA2 site of the PHOX2B promoter and the homeodomain binding site of the PHOX2A promoter revealed the presence of one conserved ATTA motif close to a second incomplete motif (in italics in Fig. 7C and 7D), we can reasonably speculate that the more intense retarded band observed in our experiments was probably formed by the binding of PHOX2B as a dimer (Fig. 7C and 7D, lane 1, complex I). This suggests that the HD + Cter protein retained its ability to bind DNA as a monomer (complex IIa), but only partially as a dimer (complex Ia). Interestingly, the antibody against the HA tag fused to the HD + Cter protein super-shifted a more intense band than that obtained using the PHOX2B WT-HA protein, thus suggesting that the deletion of the N-terminal domain affected the dimer DNA binding affinity but not its formation (Fig. 7C and 7D, lane 6, **). Notably, faint bands were also observed using the Nter + HD protein, thus suggesting that it might form dimers *in vitro* (Fig. 7C and 7D, lane 9, ***).

The polyalanine expanded tract interferes with each localisation signal and blocks PHOX2B homeodomain-mediated import

Our results show that dimerisation is impaired when the polyalanine stretch is elongated. Given that previous experiments have shown that nuclear import and DNA binding are also progressively reduced by polyalanine tract expansion (19-21), and that the homeodomain presumably plays a central role in all PHOX2B functions (i.e. nuclear import, DNA binding, and dimerisation), we further characterised the role of the C-terminal region in modulating homeodomain activity, focusing our attention on nuclear import process.

Nuclear localisation sequences (NLSs) are quite variable but generally consist of basic residues (40) and, in the case of homeodomain proteins, an NLS is often found within or adjacent to the homeodomain itself (41-45). PHOX2B protein contains two stretches of highly basic amino acids at both ends of the homeodomain (respectively encompassing amino acids 95–102 and 148–155; Fig. 9A). In order to clarify further the nuclear import of PHOX2B, we identified and characterised PHOX2B NLSs. To confirm the role of the homeodomain in nuclear import of the protein, we cloned the same fragments of the PHOX2B protein (downstream of the smaller HA tag) as those used in the mammalian two-hybrid experiments (Fig. 8A), in order to exclude the possible effects of the heterologous nuclear signal of the VP16 AD tag on protein import, and analysed their subcellular localisation by means of immunohistochemistry. We detected cells transfected with all of the truncated constructs except for Nter (corresponding to the N-terminal region), which was only detectable when a Myc tag was cloned downstream of the Nter region (Fig. 8B, panels d-f) probably because it makes the protein more stable. This confirms that, as previously reported by Wu *et al.* (46), the N-terminal domain of PHOX2B is extremely unstable.

Nuclear staining was only observed when the expressed truncated proteins were those containing the homeodomain and lacking the C-terminal (Nter + HD) or N-terminal region (HD + Cter) (Fig. 8B, panels g-i and o-q), thus confirming that the HD is required for nuclear localisation (47). Moreover, the HD *per se* localised in the nucleus, whereas the N-terminal (Nter) and C-terminal (Cter) regions were excluded from it, thus indicating that the HD is both required and sufficient for nuclear import (Fig. 8B, compare panels l-n (HD) with panels d-f (Nter) and r-t (Cter)). It is worth noting that all of the cells transfected with one of the two constructs containing the N-terminal domain (Nter and Nter + HD, Fig. 8B, panels d-i) respectively showed very strong cytoplasmic and nuclear aggregation, thus suggesting that the C-terminal portion of PHOX2B plays a role in keeping the protein in a soluble state, as in the case of the wild-type protein (Fig. 8B, panels a-c) and the truncated constructs containing the C-terminus (Fig. 8B, panels o-t). Remarkably, the

peculiar dot-like pattern of the N-ter + HD protein showed that the truncated protein is localised in specific foci, corresponding to nuclear regions with weak DAPI staining, which seem to be distinct from the nucleoli surrounded by a characteristic ring of DAPI-positive chromatin (marked with the asterisks in Fig. 8B, zoomed view of the indicated area in panel i).

To characterise the role of the two stretches of basic residues at both ends of the homeodomain, we first generated a construct encoding a protein carrying the deletion of the entire HD except for the two putative NLSs (PHOX2B Δ 106-147, Fig. 9B). As shown in Fig. 9B (panels a-c), the deletion did not affect nuclear localisation, thus suggesting that the two regions (or at least one) are required for PHOX2B nuclear import.

In order to examine the functional role of each NLS motif in PHOX2B nuclear localisation, we introduced deletions into the PHOX2B expression vector that eliminated one or both stretches.

Deletion of the proximal NLS (PHOX2B Δ NLS1) led to nuclear staining of the fusion protein with substantial cytoplasmic fluorescence (Fig. 9B, panels d-f), whereas deletion of the NLS2 region (PHOX2B Δ NLS2) led to a more marked cytoplasmic localisation (Fig. 9B, panels g-i). However, in both cases, the DAPI staining was distorted, and we observed nuclear inclusions corresponding to DAPI-negative regions that resembled the findings obtained when the Nter + HD deletion construct was over-expressed (compare Fig. 9B, panels d-i, with Fig. 8B, panels g-i).

PHOX2B carrying deletions of both NLS motifs (PHOX2B Δ NLS1-2) accumulated in the cytoplasm around the nucleus (Fig. 9B, panels l-n), thus confirming that the concerted action of both regions is required for the nuclear localisation of the protein.

In order to assess the effects of the polyalanine expansions on the homeodomain-mediated nuclear import, we inserted the longest polyalanine expansion (+13) into the constructs carrying the single or double NLS deletion. As previously shown (19-21), the cells transfected with the +13 alanine mutant showed cytoplasmic staining and aggregation, as well as nuclear staining (Fig. 9C, panels a-c). Unlike the wild-type, the combined presence of the expanded polyalanine tract and the deletion of just one

NLS (PHOX2B +13 Ala Δ NLS1 and PHOX2B +13 Ala Δ NLS2) is almost sufficient to completely block protein import (compare Fig. 9C, panels d-i, with Fig. 9B, panels d-i).

Moreover, after deletion of the N-terminal domain, the presence of the C-terminal portion carrying the expanded polyalanine tract directed the homeodomain to a sub-cellular localisation that was different from that of its normal counterpart, which was localised exclusively inside the nucleus (Fig. 8B, panels o-q): a fraction of the truncated protein was in the cytoplasm and formed aggregates (Fig. 9D, panels d-f), thus suggesting that the expanded C-terminus actively interferes with the correct folding of the homeodomain, leading to aggregation. Interestingly, the expanded C-terminal domain localised diffusely in the cytoplasm, like the C-terminal carrying the normal polyalanine tract (Fig. 8B, panels r-t) thus indicating that the polyalanine tract *per se* does not massively aggregate (Fig. 9D, panels a-c).

The above experiments indicate that the nuclear import of the protein is regulated by the homeodomain, and that the expanded C-terminus interferes with this process.

DISCUSSION

In the first part of this study we analysed the dimerisation properties of PHOX2B wild-type and mutant proteins, and their possible interactions, in a cell model using co-immunoprecipitation and a mammalian two-hybrid system; the analyses confirmed the formation of wild-type homodimers, as already shown *in vitro* (7,20), the formation of mutant homodimers/oligomers (although the interactions observed by measuring luciferase activity in mammalian two-hybrid experiments are weaker than those observed in the homodimers of wild-type protein, probably due to the partial mislocalisation of the GAL4 BD-tagged expanded proteins), and indicated that expanded PHOX2B mutants interact weakly with wild-type protein.

As in the case of wild-type:mutants heterodimers, we detected functional weak interactions only in HeLa cells by the mammalian two-hybrid system, and taking into account that this experimental approach forces proteins into the nucleus and converts an

interaction into a defined transcriptional readout, we also considered the possibility that the tendency to aggregation shown by the expanded proteins could interfere with the correct folding of the VP16-tagged expanded proteins, or that the formation of heterodimers do not reconstitute a functional transcription factor. However, we reasonably excluded both hypotheses because we were able to detect the formation of mutants homodimers and heterodimers with PHOX2A, although we cannot rule out the possibility that oligomers are formed, because two-hybrid systems have been successfully used to study the oligomerisation of aggregation-prone proteins (particularly polyglutamine and polyalanine expanded proteins), thus suggesting that this assay is not intrinsically impaired by protein aggregation (35,48). Interestingly, our data indicate that also the mutant with short (+7) alanine expansion, although still able to partially form homodimers *in vitro* (20), dramatically reduces its ability to dimerise with its wild-type counterpart. Moreover, the same defects have been observed with the mutant carrying the longest expansion (+13 alanine), and the slight higher luciferase activity measured may correlate with its partial ability to sequester the wild-type protein in the nuclear and cytoplasmic aggregates (19,21,22).

Therefore, our data exclude the idea that polyalanine expanded mutants can form strong dimers with wild-type protein, and that the formation of non-functional heterodimers may play a major role in CCHS pathogenesis.

In this study we also analysed the dimerisation properties of PHOX2A and its ability to form heterodimers with PHOX2B wild-type and mutant proteins. Co-immunoprecipitation experiments showed similar interactions among PHOX2B mutated proteins and the wild-type counterpart or PHOX2A, but conversely, mammalian two-hybrid system showed that PHOX2B and PHOX2A appear to have different interaction properties. Although the homeodomains of PHOX2B and PHOX2A are identical, we measured significant different strengths of the interactions in the respective homodimers and, interestingly, our data indicate that the formation of PHOX2A:PHOX2B heterodimers is direction-dependent, suggesting a role for other domains of the proteins in modulating these interactions. Several lines of

evidence *in vivo* showed that the two proteins are not functional equivalent, and given that their C-terminal domains are very different and the role of the C-terminal domain of PHOX2B in homodimerisation, it is reasonable to suppose that the formation of homo or heterodimers may be responsible for the creation of different interfaces for differential binding of cofactors. Moreover, the partial ability of PHOX2B mutated proteins to form heterodimers with PHOX2A, with a comparable affinity to PHOX2A homodimers (at least for shorter expansions), suggests the possible presence of species of dimers that differ from conventional homo and heterodimers.

The hypothesis that PHOX2B mutants may inhibit PHOX2A function in a dominant-negative manner has been first suggested by Trochet et al. (20); however, in that study, PHOX2A nuclear localisation was not affected by the over-expression of +13 alanine mutant. Moreover, the recent data reporting specific defects in Locus Coeruleus development in two human cases of CCHS (one of which carrying +7 alanine mutation) (49), and given that PHOX2A is required for LC differentiation (50), has favoured, once again, the hypothesis that PHOX2B mutant proteins may exert dominant-negative effects on PHOX2A function. Our results with the *DBH* promoter suggest that PHOX2B mutants do not interfere with the transcriptional activity of PHOX2A, but, conversely, PHOX2A is able to synergise with PHOX2B mutants (and this effect is clearly evident at least with the +7 alanine mutant). This observation was unexpected and uncovers additional interesting characteristics of PHOX2B mutants that open the possibility that they may not be simply misfolded and not functional molecules. Our data indicate first that, although the reduced transcriptional activity, probably due to the diminished DNA binding, they have a (partial) conserved ability to interact with other components of the transcriptional complex and transcriptional activators; second, that their defects can be partially counteracted by the interaction with molecules (such as PHOX2A) able to tether them to the promoter of target genes. However, as the nature of the interactors could vary according to the promoter, and we cannot exclude the possibility of new “toxic” interactions, the possible protective role of

PHOX2A needs to be further elucidated and investigated. Although we are probably underestimating the interactions among mutants, because of the partial mislocalization of the GAL4 BD tagged expanded proteins, our findings indicate that the mutants are able to form homodimers and both the homeodomain and the C-terminus are required; therefore, we can reasonably hypothesise that the expansion causes a conformational change in the C-terminal domain that partially blocks interactions between mutant and wild-type, but not those between mutants (or between mutants and PHOX2A), and that a strong structural constraint on the length of the polyalanine tract is necessary to impose the correct spatial distance and orientation between the homeodomain and the C-terminal region.

Our findings on PHOX2B nuclear import also support the idea of cross-talk between the homeodomain and the C-terminus insofar as they show that PHOX2B has two strong functional cooperative NLSs in the homeodomain (a weaker NLS1 in the N-terminal arm and a stronger NLS2 in helix III), and that the polyalanine expansion alters their functionality. In line with this, we found that the polyalanine expanded tract *per se* does not lead to visible intracellular aggregation, as the cytoplasmic signal of the C-terminus with the expanded polyalanine tract was diffuse and comparable with that of the wild-type counterpart and the addition of the homeodomain to the expanded C-terminus not only strongly shifts the protein into the nucleus, but also causes its partial aggregation in the cytoplasm. As the homeodomain itself apparently does not aggregate, this suggests that the expanded C-terminus actively interferes with its correct folding. Nuclear transport is a highly regulated process, and the proteins to be transported into or out of the nucleus are bound by transport receptors that recognise the NLSs in the cargo protein. One mechanism regulating protein nuclear import is to modulate the binding affinity of the transport receptor for the NLS-cargo, which may occur in various ways: i) the intermolecular masking of the NLS by a second macromolecule; ii) the intramolecular masking of the NLS as a result of a post-translational modification within the NLS; and iii) the intramolecular/interdomain masking of the NLS

due to the protein taking on an inhibitory conformation. We favour the idea that the normal C-terminus adopts an “open” conformation that allows the homeodomain to function correctly and is then masked by the expanded C-terminus in such a way as to prevent dimerisation, DNA binding and nuclear localisation. A similar mechanism has been proposed for another homeoprotein containing an alanine stretch (Extradenticle, the drosophila homologue of PBX1A) and, interestingly, the authors suggest that the stretch itself might be important for maintaining the correct conformation for protein nuclear localisation (51). Another possible mechanism is the decreased release in the nucleus of the mutated cargo by transport receptors, as already reported for another homeoprotein (ARX, (52)).

Unexpectedly, our findings indicate that, although unstable, the N-terminal region of the protein massively aggregates. Furthermore, the addition of the homeodomain to the N-terminal portion of PHOX2B is sufficient to stabilise it (thus forcing the protein into the nucleus), but apparently does not block the aggregation process. In agreement with our data, it has been shown that the K155X mutant (found in a CCHS patient), which lacks the entire C-terminus, aggregates in both the nucleus and the cytoplasm. This is probably because of the absence of the last three residues of the homeodomain which, as has been previously shown, are important for the NLS2 activity (31). Alternatively, as the truncated proteins accumulates in nuclear regions with weak DAPI staining, which seem to be distinct from the nucleoli surrounded by a characteristic ring of DAPI-positive chromatin, we cannot rule out the possibility that, instead of aggregating, the truncated protein is localised in specific foci. The different pattern observed with the HD + Cter protein, which was indistinguishable from that of the full-length protein, suggests that the C-terminal domain plays a major role in protein solubility and, possibly, protein targeting to the proper subnuclear regions. This is probably a result of greater DNA-binding affinity, as supported by the findings of our *in vitro* gel-shift experiments showing that the deletion of the C-terminal domain greatly decreases protein DNA binding affinity. In line with this idea is the fact that the two other mutants we tested, that

completely lacked DNA binding (i.e., PHOX2B Δ NLS1 and PHOX2B Δ NLS2) showed defective subnuclear localisation. It has been shown that DNA plays a role in regulating the nuclear distribution of other transcription factors, including members of families of proteins bearing a homeodomain. An intriguing possibility is that, as the DNA binding of polyalanine expanded proteins progressively decreases as a function of the length of the polyalanine tract, the subnuclear localisation of mutants might be slightly different, although by immunofluorescence the nuclear pattern of proteins with shorter polyalanine expansions is virtually identical to that of wild-type protein. Nuclear import defects and cytoplasmic aggregation are detectable only in the case of proteins with longer expansions and our previous data indicated that the formation of aggregates is dependent on protein abundance (21,53). Several evidence regarding other polyalanine proteins, suggest that massive over-expression of the protein might trigger the aggregation process and prevent nuclear import *per se*. Moreover, there are no data on *in vivo* aggregation of PHOX2B protein available, and the debate concerning the involvement of aggregates and their toxicity in CCHS is still open. Nevertheless, our data indicate that the expansion of the polyalanine tract diminishes the efficiency of the homeodomain-mediated protein nuclear import, in comparison to wild-type protein, and together with previous data, our findings indicate that the C-terminal domain is an important modulator of DNA-binding, homeodomain-mediated dimerisation, and solubility of the protein and that the length of the polyalanine tract is critical to drive the folding of the C-terminal domain, which would in turn influence the spatial orientation of the homeodomain and all its functions.

Moreover, our data exclude the possibility that the formation of non-functional heterodimers between the wild-type protein and mutants with both short and long expansions may play a major role in CCHS pathogenesis. On the other hand, our findings suggest that PHOX2B mutants may form heterodimers with PHOX2A, with possible different biochemical properties from those of the homodimers.

ACKNOWLEDGEMENTS

This study was supported by the Telethon Foundation [grant No. GGP13055] to D.F. and the Associazione Italiana per la Sindrome da Ipoventilazione Centrale Congenita (A.I.S.I.C.C.).

We are grateful to the Associazione Italiana per la Sindrome da Ipoventilazione Centrale Congenita (A.I.S.I.C.C.) and to all CCHS patients and their families. We would like to thank Kevin Smart for his help in preparing the manuscript. We would also like to thank Monzino Foundation (Milan, Italy) for its generous gift of the Zeiss LSM 510 Meta confocal microscope.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

AUTHOR CONTRIBUTIONS

SDL and DB designed, performed and analyzed the experiments and wrote the paper. RB designed and analyzed the experiments. DF conceived and coordinated the study. RB and DF revised the paper critically for important intellectual content. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

1. Coleman, M., Boros, S. J., Huseby, T. L., and Brennom, W. S. (1980) Congenital central hypoventilation syndrome. A report of successful experience with bilateral diaphragmatic pacing. *Arch. Dis. Child.* **55**, 901-903
2. Amiel, J., Laudier, B., Attié-Bitach, T., Trang, H., de Pontual, L., Gener, B., Trochet, D., Etchevers, H., Ray, P., Simonneau, M., Vekemans, M., Munnich, A., Gaultier, C., and Lyonnet, S. (2003) Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. *Nat. Genet.* **33**, 459-461
3. Trochet, D., O'Brien, L. M., Gozal, D., Trang, H., Nordenskjöld, A., Laudier, B., Svensson, P. J., Uhrig, S., Cole, T., Niemann, S., Munnich, A., Gaultier, C., Lyonnet, S., and Amiel, J. (2005) PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. *Am. J. Hum. Genet.* **76**, 421-426
4. Vanderlaan, M., Holbrook, C. R., Wang, M., Tuell, A., and Gozal, D. (2004) Epidemiologic survey of 196 patients with congenital central hypoventilation syndrome. *Pediatr. Pulmonol.* **37**, 217-229
5. Pattyn, A., Morin, X., Cremer, H., Goridis, C., and Brunet, J. F. (1999) The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. *Nature* **399**, 366-370
6. Pattyn, A., Morin, X., Cremer, H., Goridis, C., and Brunet, J. F. (1997) Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. *Development* **124**, 4065-4075
7. Adachi, M., Browne, D., and Lewis, E. J. (2000) Paired-like homeodomain proteins Phox2a/Arx and Phox2b/NBPhox have similar genetic organization and independently regulate dopamine beta-hydroxylase gene transcription. *DNA Cell Biol.* **19**, 539-554
8. Matera, I., Bachetti, T., Puppo, F., Di Duca, M., Morandi, F., Casiraghi, G. M., Cilio, M. R., Hennekam, R., Hofstra, R., Schöber, J. G., Ravazzolo, R., Ottonello, G., and Ceccherini, I. (2004) PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome. *J. Med. Genet.* **41**, 373-380
9. Weese-Mayer, D. E., Berry-Kravis, E. M., Zhou, L., Maher, B. S., Silvestri, J. M., Curran, M. E., and Marazita, M. L. (2003) Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b. *Am. J. Med. Genet. A* **123A**, 267-278
10. D'Elia, A. V., Tell, G., Paron, I., Pellizzari, L., Lonigro, R., and Damante, G. (2001) Missense mutations of human homeoboxes: A review. *Hum. Mutat.* **18**, 361-374
11. Green, H., and Wang, N. (1994) Codon reiteration and the evolution of proteins. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 4298-4302
12. Lavoie, H., Debeane, F., Trinh, Q. D., Turcotte, J. F., Corbeil-Girard, L. P., Dicaire, M. J., Saint-Denis, A., Pagé, M., Rouleau, G. A., and Brais, B. (2003) Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. *Hum. Mol. Genet.* **12**, 2967-2979
13. Karlin, S., and Burge, C. (1996) Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 1560-1565
14. Goodman, F. R., Mundlos, S., Muragaki, Y., Donnai, D., Giovannucci-Uzielli, M. L., Lapi, E., Majewski, F., McGaughan, J., McKeown, C., Reardon, W., Upton, J., Winter, R. M.,

- Olsen, B. R., and Scambler, P. J. (1997) Synpolydactyly phenotypes correlate with size of expansions in HOXD13 polyalanine tract. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 7458-7463
15. Amiel, J., Trochet, D., Clément-Ziza, M., Munnich, A., and Lyonnet, S. (2004) Polyalanine expansions in human. *Hum. Mol. Genet.* **13 Spec No 2**, R235-243
 16. Brown, L. Y., and Brown, S. A. (2004) Alanine tracts: the expanding story of human illness and trinucleotide repeats. *Trends Genet.* **20**, 51-58
 17. Messaed, C., and Rouleau, G. A. (2009) Molecular mechanisms underlying polyalanine diseases. *Neurobiol. Dis.* **34**, 397-405
 18. Shinchuk, L. M., Sharma, D., Blondelle, S. E., Reixach, N., Inouye, H., and Kirschner, D. A. (2005) Poly-(L-alanine) expansions form core beta-sheets that nucleate amyloid assembly. *Proteins* **61**, 579-589
 19. Bachetti, T., Matera, I., Borghini, S., Di Duca, M., Ravazzolo, R., and Ceccherini, I. (2005) Distinct pathogenetic mechanisms for PHOX2B associated polyalanine expansions and frameshift mutations in congenital central hypoventilation syndrome. *Hum. Mol. Genet.* **14**, 1815-1824
 20. Trochet, D., Hong, S. J., Lim, J. K., Brunet, J. F., Munnich, A., Kim, K. S., Lyonnet, S., Goridis, C., and Amiel, J. (2005) Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. *Hum. Mol. Genet.* **14**, 3697-3708
 21. Di Lascio, S., Bachetti, T., Saba, E., Ceccherini, I., Benfante, R., and Fornasari, D. (2013) Transcriptional dysregulation and impairment of PHOX2B auto-regulatory mechanism induced by polyalanine expansion mutations associated with congenital central hypoventilation syndrome. *Neurobiol. Dis.* **50**, 187-200
 22. Parodi, S., Di Zanni, E., Di Lascio, S., Bocca, P., Prigione, I., Fornasari, D., Pennuto, M., Bachetti, T., and Ceccherini, I. (2012) The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B. *J. Mol. Med. (Berl.)* **90**, 1025-1035
 23. Ge, L., and Rudolph, P. (1997) Simultaneous introduction of multiple mutations using overlap extension PCR. *Biotechniques* **22**, 28-30
 24. Benfante, R., Flora, A., Di Lascio, S., Cargnin, F., Longhi, R., Colombo, S., Clementi, F., and Fornasari, D. (2007) Transcription factor PHOX2A regulates the human alpha3 nicotinic receptor subunit gene promoter. *J Biol Chem* **282**, 13290-13302
 25. Cargnin, F., Flora, A., Di Lascio, S., Battaglioli, E., Longhi, R., Clementi, F., and Fornasari, D. (2005) PHOX2B regulates its own expression by a transcriptional auto-regulatory mechanism. *J. Biol. Chem.* **280**, 37439-37448
 26. Flora, A., Lucchetti, H., Benfante, R., Goridis, C., Clementi, F., and Fornasari, D. (2001) Sp proteins and Phox2b regulate the expression of the human Phox2a gene. *J. Neurosci.* **21**, 7037-7045
 27. Battaglioli, E., Gotti, C., Terzano, S., Flora, A., Clementi, F., and Fornasari, D. (1998) Expression and transcriptional regulation of the human alpha3 neuronal nicotinic receptor subunit in T lymphocyte cell lines. *J. Neurochem.* **71**, 1261-1270
 28. Terzano, S., Flora, A., Clementi, F., and Fornasari, D. (2000) The minimal promoter of the human alpha 3 nicotinic receptor subunit gene. Molecular and functional characterization. *J. Biol. Chem.* **275**, 41495-41503
 29. Yang, C., Kim, H. S., Seo, H., Kim, C. H., Brunet, J. F., and Kim, K. S. (1998) Paired-like homeodomain proteins, Phox2a and Phox2b, are responsible for noradrenergic cell-specific transcription of the dopamine beta-hydroxylase gene. *J. Neurochem.* **71**, 1813-1826
 30. Seo, H., Hong, S. J., Guo, S., Kim, H. S., Kim, C. H., Hwang, D. Y., Isacson, O., Rosenthal, A., and Kim, K. S. (2002) A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. *J. Neurochem.* **80**, 905-916
 31. Trochet, D., Mathieu, Y., Pontual, L., Savarirayan, R., Munnich, A., Brunet, J. F., Lyonnet, S., Goridis, C., and Amiel, J. (2009) In Vitro studies of non poly alanine PHOX2B mutations

- argue against a loss-of-function mechanism for congenital central hypoventilation. *Hum. Mutat.* **30**, E421-431
32. Chalepakis, G., Jones, F. S., Edelman, G. M., and Gruss, P. (1994) Pax-3 contains domains for transcription activation and transcription inhibition. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 12745-12749
 33. Tang, H. K., Singh, S., and Saunders, G. F. (1998) Dissection of the transactivation function of the transcription factor encoded by the eye developmental gene PAX6. *J. Biol. Chem.* **273**, 7210-7221
 34. Furukawa, K., Iioka, T., Morishita, M., Yamaguchi, A., Shindo, H., Namba, H., Yamashita, S., and Tsukazaki, T. (2002) Functional domains of paired-like homeoprotein Cart1 and the relationship between dimerization and transcription activity. *Genes Cells* **7**, 1135-1147
 35. Oma, Y., Kino, Y., Toriumi, K., Sasagawa, N., and Ishiura, S. (2007) Interactions between homopolymeric amino acids (HPAAs). *Protein Sci.* **16**, 2195-2204
 36. Kim, H. S., Seo, H., Yang, C., Brunet, J. F., and Kim, K. S. (1998) Noradrenergic-specific transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2a-binding sites. *J Neurosci* **18**, 8247-8260
 37. Rychlik, J. L., Gerbasi, V., and Lewis, E. J. (2003) The interaction between dHAND and Arix at the dopamine beta-hydroxylase promoter region is independent of direct dHAND binding to DNA. *J Biol Chem* **278**, 49652-49660
 38. Bruun, J. A., Thomassen, E. I., Kristiansen, K., Tylden, G., Holm, T., Mikkola, I., Bjørkøy, G., and Johansen, T. (2005) The third helix of the homeodomain of paired class homeodomain proteins acts as a recognition helix both for DNA and protein interactions. *Nucleic Acids Res.* **33**, 2661-2675
 39. Hong, S. J., Kim, C. H., and Kim, K. S. (2001) Structural and functional characterization of the 5' upstream promoter of the human Phox2a gene: possible direct transactivation by transcription factor Phox2b. *J. Neurochem.* **79**, 1225-1236
 40. Jans, D. A., Xiao, C. Y., and Lam, M. H. (2000) Nuclear targeting signal recognition: a key control point in nuclear transport? *Bioessays* **22**, 532-544
 41. Abu-Shaar, M., Ryoo, H. D., and Mann, R. S. (1999) Control of the nuclear localization of Extradenticle by competing nuclear import and export signals. *Genes Dev.* **13**, 935-945
 42. Berthelsen, J., Kilstrup-Nielsen, C., Blasi, F., Mavilio, F., and Zappavigna, V. (1999) The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. *Genes Dev.* **13**, 946-953
 43. Bryan, J. T., and Morasso, M. I. (2000) The Dlx3 protein harbors basic residues required for nuclear localization, transcriptional activity and binding to Msx1. *J. Cell Sci.* **113 (Pt 22)**, 4013-4023
 44. Fei, Y., and Hughes, T. E. (2000) Nuclear trafficking of photoreceptor protein crx: the targeting sequence and pathologic implications. *Invest. Ophthalmol. Vis. Sci.* **41**, 2849-2856
 45. Parker, G. E., Sandoval, R. M., Feister, H. A., Bidwell, J. P., and Rhodes, S. J. (2000) The homeodomain coordinates nuclear entry of the Lhx3 neuroendocrine transcription factor and association with the nuclear matrix. *J. Biol. Chem.* **275**, 23891-23898
 46. Wu, H. T., Su, Y. N., Hung, C. C., Hsieh, W. S., and Wu, K. J. (2009) Interaction between PHOX2B and CREBBP mediates synergistic activation: mechanistic implications of PHOX2B mutants. *Hum. Mutat.* **30**, 655-660
 47. Raabe, E. H., Laudenslager, M., Winter, C., Wasserman, N., Cole, K., LaQuaglia, M., Maris, D. J., Mosse, Y. P., and Maris, J. M. (2008) Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. *Oncogene* **27**, 469-476
 48. Fan, X., Dion, P., Laganieri, J., Brais, B., and Rouleau, G. A. (2001) Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. *Hum. Mol. Genet.* **10**, 2341-2351
 49. Nobuta, H., Cilio, M. R., Danhaive, O., Tsai, H. H., Tupal, S., Chang, S. M., Murnen, A., Kreitzer, F., Bravo, V., Czeisler, C., Gokozan, H. N., Gygli, P., Bush, S., Weese-Mayer, D.

- E., Conklin, B., Yee, S. P., Huang, E. J., Gray, P. A., Rowitch, D., and Otero, J. J. (2015) Dysregulation of locus coeruleus development in congenital central hypoventilation syndrome. *Acta Neuropathol.*
50. Morin, X., Cremer, H., Hirsch, M. R., Kapur, R. P., Goridis, C., and Brunet, J. F. (1997) Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene *Phox2a*. *Neuron* **18**, 411-423
51. Stevens, K. E., and Mann, R. S. (2007) A balance between two nuclear localization sequences and a nuclear export sequence governs extradenticle subcellular localization. *Genetics* **175**, 1625-1636
52. Shoubridge, C., Tan, M. H., Fullston, T., Cloosterman, D., Coman, D., McGillivray, G., Mancini, G. M., Kleefstra, T., and Géczy, J. (2010) Mutations in the nuclear localization sequence of the *Aristaless* related homeobox; sequestration of mutant ARX with IPO13 disrupts normal subcellular distribution of the transcription factor and retards cell division. *Pathogenetics* **3**, 1
53. Di Zanni, E., Bachetti, T., Parodi, S., Bocca, P., Prigione, I., Di Lascio, S., Fornasari, D., Ravazzolo, R., and Ceccherini, I. (2012) In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins. *Neurobiol. Dis.* **45**, 508-518

FIGURE LEGENDS

FIGURE 1. Homodimerisation of PHOX2B wild-type protein. A, representative immunoblotting images of co-immunoprecipitation of MYC- and HA-tagged PHOX2B proteins, in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-MYC antibody or control immunoglobulin (IgG) and immunoblotted with anti-MYC (upper panel) and anti-HA antibodies (lower panel). B, representative immunofluorescence images of the localisation of the GAL4 BD- and VP16 AD-tagged PHOX2B WT fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (panels c and d). The nuclei were visualised using DAPI (panels a and b), and merged with the proteins detected by the anti-PHOX2B antibody (panels e and f). Scale bars: 10 μ m. C, and D, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C (C) or HeLa cells (D) with a combination of equimolar amounts of a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT) and the empty vector containing VP16 AD (*hatched bars*), or with a combination of equimolar amounts of both GAL4 BD and VP16 wild-type fusion proteins (*black bars*). Non-specific interactions were excluded upon co-transfection of PHOX2B fused to VP16 AD with VP16 AD or GAL4 BD (*light and dark grey bars*). The background level of firefly luciferase expression from the pG5LUC vector was determined upon co-transfection with empty vectors containing GAL4 BD and VP16 AD (*white bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (C and D, N=5), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein (=1). *Significant differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.05$); ***significant differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.001$).

FIGURE 2. Heterodimerisation of PHOX2B polyalanine expanded mutants with wild-type protein. A, representative immunoblotting images of co-immunoprecipitation of HA-tagged PHOX2B protein along with MYC-tagged PHOX2B polyalanine expanded mutants, in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-HA antibody or control immunoglobulin (IgG) and immunoblotted with anti-HA (upper panel) and anti-MYC antibodies (lower panel). B, representative immunofluorescence images of the localisation of the VP16 AD-PHOX2B +7Ala and VP16 AD-PHOX2B +13 Ala fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (panels c and d). The nuclei were visualised using DAPI (panels a and b), and merged to the proteins detected by the anti-PHOX2B antibody (panels e and f). Scale bars: 10 μ m. C, and D, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C (C) or HeLa cells (D) with a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT) in combination with the empty vector containing VP16 AD (*hatched bars*), the VP16 wild-type fusion protein (*black bars*), or the VP16-PHOX2B fusion protein carrying polyalanine expansions (*cross-hatched bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (C and D, N=5), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein (=1). ***Significant differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.001$).

FIGURE 3. Homodimerisation of PHOX2B polyalanine expanded mutants. A, representative immunofluorescence images of the localisation of the GAL4 BD-PHOX2B +7Ala and GAL4 BD-PHOX2B +13 Ala fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (panels c and d). The nuclei were visualised using DAPI (panels a and b), and merged with the proteins detected by the anti-PHOX2B antibody (panels e and f). Scale bars: 10 μ m. B, and C, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C cells with a vector containing the cDNA of PHOX2B +7 Ala fused to GAL4 BD (GAL4 BD-PHOX2B +7 Ala in Fig. 3B) or the cDNA of PHOX2B +13

Ala fused to GAL4 BD (GAL4 BD-PHOX2B +13 Ala in Fig. 3C), in combination with the empty vector containing VP16 AD (*hatched bars*), VP16 wild-type fusion protein (*cross-hatched bars*), or VP16-PHOX2B fusion protein carrying +7 (Fig. 3B) or +13 (Fig. 3C) alanine expansions (*black bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (B and C, N=4), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B +7 Ala protein or the GAL4 BD-PHOX2B +13 Ala protein (=1). ***Significant differences from the activity of the PHOX2B protein + 7 or +13 alanine fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.001$). D, representative immunoblotting images of co-immunoprecipitation of HA-tagged PHOX2B polyalanine expanded mutants along with MYC-tagged PHOX2B wild-type and mutant variants, in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-HA antibody or control immunoglobulin (IgG) and immunoblotted with anti-HA (upper panel) and anti-MYC antibodies (lower panel).

FIGURE 4. Homodimerisation of PHOX2A protein and its heterodimerisation with PHOX2B wild-type protein and with polyalanine expanded mutants. A, and B, representative immunoblotting images of co-immunoprecipitation of MYC-tagged PHOX2A along with HA-tagged PHOX2A, PHOX2B (A), and PHOX2B polyalanine expanded mutants (B), in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-MYC antibody or control immunoglobulin (IgG) and immunoblotted with anti-MYC (upper panels) and anti-HA antibodies (lower panels). H.E.=higher exposure. C, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT) in combination with the VP16 wild-type fusion protein (*black bar*), or the VP16-PHOX2A (*cross-hatched bar*); white, grey and hatched bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of PHOX2A fused to GAL4 BD (GAL4 BD-PHOX2A) in combination with the VP16-PHOX2A fusion protein (*white bar*), VP16-PHOX2B wild-type fusion protein (*grey bar*), or the VP16-PHOX2B fusion proteins carrying polyalanine expansions (*hatched bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (N=4), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein in combination with the VP16-PHOX2B wild-type fusion protein (=1). ***Significant differences from the luciferase activity due to the wild-type protein homodimerisation (ANOVA, Tukey's test, $p < 0.001$). D, and E, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of PHOX2A fused to GAL4 BD (GAL4 BD-PHOX2A) in combination with the VP16-PHOX2A fusion protein (D, *white bar*), or the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT) in combination with the VP16 wild-type fusion protein (E, *white bar*). Black and hatched bars indicate the transcriptional activity of the pG5LUC reporter upon the co-transfection of the above plasmids with equimolar amounts of a vector encoding PHOX2B WT (*black bars*), or PHOX2B mutants (*hatched bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (D and E, N=3), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2A protein (=1, in D) or the GAL4 BD-PHOX2B WT protein (=1, in E). ***Significant differences from the luciferase activity due to PHOX2B or PHOX2A homodimerisation (ANOVA, Tukey's test, $p < 0.001$).

FIGURE 5. Molecular effects of co-expressing the polyalanine expanded mutants and PHOX2A on their transcriptional activity and DNA binding properties. A, luciferase assays. The bars indicate the transcriptional activity of *DBH* promoter reporter construct upon co-transfection in HeLa cells with expression vectors containing the cDNA of PHOX2B WT protein (bar 2), of PHOX2A (bar 8) or carrying the expanded polyalanine tracts (bars 3 and 4); bars 5, 6, 7, 9 and 10 indicate the

transcriptional activity of *DBH* promoter reporter construct upon co-transfection in HeLa cells with a combination of equimolar amounts of the indicated expression vectors. pcDNA3 indicates the empty vector used as negative control (bar 1). The results are mean values \pm SD (error bars) of the transcriptional activity of the constructs of at least three experiments performed in triplicate (N=3), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the empty vector (=1). ***Significant differences from the luciferase activity of the reporter plasmid co-transfected with PHOX2A encoding vector (ANOVA, Tukey's test); n.s.= not significant (ANOVA, Tukey's test). B, gel shift assays using the oligonucleotide probe corresponding to a region of the *DBH* promoter containing the ATTA core motif known to bind PHOX2A and PHOX2B. At the top, the sequence of the oligonucleotide used as probe: the ATTA core motif is underlined and the incomplete motif is in italics. The labelled probe was incubated with *in vitro* expressed PHOX2A (lanes 3-5), PHOX2B wild-type protein (lanes 6-8), PHOX2B +7Ala (lanes 9-11), PHOX2B +13 Ala proteins (lanes 12-14), or a combination of equimolar amounts of the indicated proteins (lanes 15-26). The *in vitro* translated pcDNA3 empty vector was used as a control to exclude non-specific interactions (lane 2). The competitions were carried out by adding a molar excess of unlabelled oligonucleotide (lanes 4, 7, 10, 13, 16, 20, and 24). Supershift experiments were performed by pre-incubating the *in vitro* expressed proteins with anti-PHOX2A (lanes 5, 17, 21 and 25) or anti-PHOX2B antibodies (lanes 8, 11, 14, 18, 22, 26). The roman number and the asterisk on the left indicate the specific retarded complexes obtained and the super-shifted complexes containing PHOX2A or PHOX2B. The free probes are shown at the bottom of the gels.

FIGURE 6. Homodimerisation of PHOX2B protein lacking the polyalanine tract and its heterodimerisation with wild-type protein. A, representative immunofluorescence images of the localisation of the GAL4 BD- and VP16 AD-PHOX2B Δ Ala fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (panels c and d). The nuclei were visualised using DAPI (panels a and b) and merged with the proteins detected by the anti-PHOX2B antibody (panels e and f). Scale bars: 10 μ m. B, and C, luciferase assays of heterodimerisation with the WT protein (B) or homodimerisation (C) of PHOX2B Δ Ala protein. The bars indicate the transcriptional activity of the pG5LUC reporter construct in HeLa cells upon co-transfection with a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT; B) or a vector containing the cDNA of the deleted protein fused to GAL4 BD (GAL4 BD-PHOX2B Δ Ala; C) in combination with the empty vector containing VP16 AD (*hatched bars*), VP16 wild-type fusion protein (*cross-hatched bars*), or VP16-PHOX2B fusion protein deleted of the polyalanine stretch (*black bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (N=5), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein (B) or GAL4 BD-PHOX2B Δ Ala protein (C) (=1). ***Significant differences from the activity of the wild-type protein fused to GAL4 BD (in B) or the GAL4 BD-PHOX2B Δ Ala (in C) (ANOVA, Tukey's test, $p < 0.001$).

FIGURE 7. Mapping of the PHOX2B dimerisation domain and contribution of the N-ter and C-ter domains to dimerisation and DNA binding of PHOX2B. A, representative immunofluorescence images of the localisation of the VP16 AD-PHOX2B deleted fusion proteins (VP16 AD-Nter, VP16 AD-Nter + HD, VP16 AD-HD, VP16 AD-HD + Cter, VP16 AD-Cter) in transfected HeLa cells stained using anti-VP16 (panels b, e and h) or anti-PHOX2B antibody (panels m and p). The nuclei were visualised using DAPI (panels a, d, g, l and o), and merged with the proteins detected by the anti-VP16 and anti-PHOX2B antibodies (panels c, f, i, n and q). Scale bars: 10 μ m. B, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct in HeLa cells upon co-transfection with a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2B WT) in combination with the empty vector containing VP16 AD (*hatched bar*), VP16 wild-type fusion protein (*black bar*), or VP16-PHOX2B deleted fusion protein shown on the left (*cross-hatched bars*). The results are the mean values \pm SD (*error bars*) of the transcriptional

activity of the constructs detected in at least three experiments performed in triplicate (N=4), and are expressed as fold-increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein (=1; *hatched bar*). *Significant differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.05$); ***significant differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey's test, $p < 0.001$); n.s.= not significant (ANOVA, Tukey's test). C, and D, gel shift assays using oligonucleotide probes corresponding to two regions of the *PHOX2B* promoter (C), or a region of the *PHOX2A* and *DBH* promoters (D) containing the ATTA core motifs known to bind PHOX2B. At the top, the sequences of the oligonucleotides used as probes: the ATTA core motif is underlined and the incomplete motif is in italics. The labelled probes were incubated with *in vitro* expressed HA-tagged PHOX2B wild-type protein (lanes 1-3 and 11-13), PHOX2B HD + Cter (lanes 4-6 and 14-16), or PHOX2B Nter + HD proteins (lanes 7-9 and 17-19). The *in vitro* translated pcDNA3 empty vector was used as a control to exclude non-specific interactions (lanes 10 and 20). The competitions were carried out by adding a molar excess of unlabelled oligonucleotide (lanes 2, 5, 8, 12, 15 and 18). Supershift experiments were performed by pre-incubating the *in vitro* expressed proteins with anti-HA antibody (lanes 3, 6, 9, 13, 16 and 19). The roman numbers on the left indicate the specific retarded complexes obtained using *in vitro* expressed PHOX2B wild-type protein (I and II) or PHOX2B HD + Cter (Ia and IIa); the asterisks indicate the super-shifted complexes containing PHOX2B. The free probes are shown at the bottom of the gels.

FIGURE 8. Contribution of the N-ter and C-ter domains to nuclear import of PHOX2B. A, Schematic representation of wild-type PHOX2B protein and its truncated constructs. All constructs were fused N-terminally to an HA epitope tag. Numbers correspond to the amino acids residues of PHOX2B. B, representative immunofluorescence images of the localisation of HA-PHOX2B truncated fusion proteins. HeLa cells were transfected with the HA-tagged proteins and analysed 48 h after transfection by means of immunofluorescence using anti HA antibody (panels b, e, h, m, p, and s); the nuclei were visualised using DAPI (panels a, d, g, l, o and r), and merged with the proteins detected by the anti-HA antibody (panels c, f, i, n, q and t). On the right of panel i, a zoomed view of the indicated area is showed; the asterisks indicate the nucleoli.

FIGURE 9. Identification of PHOX2B NLSs and effects of the polyalanine expanded tract on PHOX2B nuclear import. A, schematic representation of the PHOX2B protein showing the sequence of the homeodomain and the two putative NLSs (underlined). B, on the top, schematic representation of PHOX2B carrying deletions of the proximal NLS (Δ NLS1), distal NLS (Δ NLS2), both (Δ NLS1-2), or the entire HD except for the NLSs (Δ 106-147). The black boxes indicate the NLSs. On the bottom, representative immunofluorescence images of the subcellular localisation of HA-tagged PHOX2B deletion proteins in transfected HeLa cells stained by anti-HA antibody (panels b, e, h and m); the nuclei were visualised using DAPI (panels a, d, g and l), and merged with the HA-PHOX2B deleted proteins detected by anti-HA Ab (panels c, f, i and n). Scale bars: 10 μ m. C, representative immunofluorescence images of the subcellular localisation of HA-tagged PHOX2B carrying +13 alanine expansions (PHOX2B +13 Ala) and the expanded deletion proteins (PHOX2B +13 Ala Δ NLS1, PHOX2B +13 Ala Δ NLS2, PHOX2B +13 Ala Δ NLS1-2) in transfected HeLa cells stained by anti-HA antibody (panels b, e, h and m). The nuclei were visualised using DAPI (panels a, d, g and l), and merged with the HA-PHOX2B deleted proteins detected by anti-HA Ab (panels c, f, i and n). Scale bars: 10 μ m. D, representative immunofluorescence images of the localisation of the expanded HA-PHOX2B truncated fusion proteins. HeLa cells were transfected with the HA-tagged proteins and analysed 48 h after transfection by means of immunofluorescence using anti HA antibody (panels b and e); the nuclei were visualised using DAPI (panels a and d) and merged with the proteins detected by the anti-HA antibody (panels c and f). Scale bars: 10 μ m.

Table1. Nucleotide sequences of the synthetic primers used in the PCR amplifications to generate the deleted and mutant variants of PHOX2B. The enzyme restriction sites used for cloning are underlined.

Construct name	Primer FW (5'-3')	Primer REV(5'-3')
PHOX2B Nter	CGGAATTC <u>CAATGTATAAAAATGGAATATTC</u>	GCGAATTC <u>TCACTTGCGCTTCTCGTTG</u>
PHOX2B Nter + HD	CGGAATTC <u>CAATGTATAAAAATGGAATATTC</u>	GCGAATTC <u>TCACTCCTGCTTGCGAAAC</u>
PHOX2B HD	CGGAATTC <u>CAGCAGCGGCGCATCC</u>	GCGAATTC <u>TCACTCCTGCTTGCGAAAC</u>
PHOX2B HD + Cter	CGGAATTC <u>CAGCAGCGGCGCATCC</u>	ATGAATTC <u>GGCTTCCGCCGCAGG</u>
PHOX2B Cter	CGGAATTC <u>TTCGCAAGCAGGAGCGC</u>	ATGAATTC <u>GGCTTCCGCCGCAGG</u>
PHOX2B ΔNLS1	CTCAACGAGACCACTTTCACCAGTGCCAG	AAAGTGGTCTCGTTGAGGCCGCCGTG
PHOX2B ΔNLS2	GTTCCAGCAGGAGCGCGCAGCG	TCCTGCTGGAACACACCTGGACTCGC
PHOX2B Δ106-147	ACCACTTTCAACCGCCGCGCCAAG	CGGTTGAAAAGTGGTGCGGATGCG
External primers (for ΔNLS1, ΔNLS2, ΔNLS1-2 and Δ106-147)	CACAAGCTT <u>GCTGCGGAATTGTACC</u>	CTCCATTCGCCCCGCAGCTG
GAL4 BD-/ VP16 AD- PHOX2B WT	GGGGTACC <u>ATGTATAAAAATGGAATATTC</u>	CCGGTACC <u>GGCTTCCGCCGCAGG</u>
GAL4 BD-/ VP16 AD-Nter	GGGGTACC <u>ATGTATAAAAATGGAATATTC</u>	CCGGTACC <u>TCACTTGCGCTTCTCGTTG</u>
GAL4 BD-/ VP16 AD-Nter +HD	GGGGTACC <u>ATGTATAAAAATGGAATATTC</u>	CCGGTACC <u>TCACTTGCGCTTCTCGTTG</u>
GAL4 BD-/ VP16 AD-HD	GGGGTACC <u>CAGCAGCGGCGCATCC</u>	CCGGTACC <u>TCACTTGCGCTTCTCGTTG</u>
GAL4 BD-/ VP16 AD- HD+Cter	GGGGTACC <u>CAGCAGCGGCGCATCC</u>	CCGGTACC <u>GGCTTCCGCCGCAGG</u>
GAL4 BD-/ VP16 AD-Cter	GGGGTACC <u>CGCAAGCAGGAGCGC</u>	CCGGTACC <u>GGCTTCCGCCGCAGG</u>
GAL4 BD-/ VP16 AD- PHOX2A	<u>GCGGCCGCCGGCCGATGGACTACTCTTACC</u>	TTGCGGCCGCCTAGAAGAGATTGGTCTT CAGGGC




Fig.1




Fig.2




Fig.3





Fig.4

A



B




Fig.5




Fig.6







Fig.7







Fig.8



Alanine Expansions Associated With Congenital Central Hypoventilation Syndrome Impair PHOX2B Homeodomain-Mediated Dimerisation And Nuclear Import

Simona Di Lascio, Debora Belperio, Roberta Benfante and Diego Fornasari

J. Biol. Chem. published online April 27, 2016

Access the most updated version of this article at doi: [10.1074/jbc.M115.679027](https://doi.org/10.1074/jbc.M115.679027)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at <http://www.jbc.org/content/early/2016/04/27/jbc.M115.679027.full.html#ref-list-1>